VIGL Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Vigil Neuroscience | Updated today | Last updated: 2026-07-27

TickerVIGL

Market Capn/a

Cash RunwayUnknown

Next Catalystn/a

Public Research Snapshot

Vigil Neuroscience is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for VGL101 in ALSP (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
No intervention	ALSP	n/a	n/a	Public pipeline row
VGL101	ALSP	n/a	Phase 2	Public pipeline row
VG-3927	Healthy \| Alzheimer Disease	n/a	Phase 1	Public pipeline row
Diagnosing Adverse Drug Reactions Registry	Genetics of Drug Metabolism	n/a	n/a	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Unknown.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT01970709	n/a	UNKNOWN	250000	2015-11
NCT06343636	Phase 1	COMPLETED	115	2025-01-10
NCT05677659	Phase 2	TERMINATED	20	2025-02-14
NCT05020743	n/a	TERMINATED	56	2025-05-30

Scientific Context

literature_publication | Natural History of Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP): A Retrospective Patient Cohort Study.
literature_publication | TNF inhibition differentially impacts regional Abeta immunotherapy efficacy in the humanized hAb(SAA) mouse model.
literature_publication | Correction: Data-driven disease subgrouping in ALS: a multicenter cerebral functional connectivity study.
literature_publication | Top five Alzheimer Disease trial eligibility criteria favor men compared to women in a clinic-based cohort.
literature_publication | Unifying the Communities of Early-Onset Glycogen Storage Disease Type IV and Adult Polyglucosan Body Disease Through a Genetic Prevalence Study of GBE1-Related Disease.

Want the full VIGL research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.